TheTechno Optimist.

BGE-102 (NLRP3)BioAge Labs—BGE-102 cuts hsCRP 86% at day 14 in obese adults with raised inflammation; 93% reach normal levelsBGE-102 (NLRP3)BioAge Labs—BioAge prices an upsized $115M public stock offeringBGE-102 (NLRP3)BioAge Labs—BioAge doses first participant in QUELL-CV, a 160-person Phase 2 trial of BGE-102 in obesity with high inflammationBGE-102 (NLRP3)BioAge Labs—BioAge opens QUELL-DME, a Phase 2 trial of oral BGE-102 in diabetic macular edemaBioAge Labs—BioAge expands APJ agonist pipeline with oral small-molecule and long-acting antibody candidatesBGE-102 (NLRP3)BioAge Labs—BioAge expands BGE-102 into eye disease with a planned Phase 1b/2a trial in diabetic macular edemaBGE-102 (NLRP3)BioAge Labs—BioAge reports full BGE-102 Phase 1 data with about 85% median hsCRP reduction and no serious adverse events

APJ agonist program

by BioAge LabsUS

Novel apelin receptor APJ agonists for obesity. Multiple modalities including oral and antibody with JiKang option.

ProtoStage 2 of 5

Oral small-molecule and antibody candidates in development. First IND filing planned by end of 2026.

Checked 10 Oct0 updates this week

Milestones

Next · First APJ IND filing
  1. Azelaprag Phase 2 STRIDES halted after liver signalsDec 2024Complete.
  2. Expanded APJ pipeline with oral and antibody candidates announcedQ1 2026Complete.
  3. First APJ IND filingTarget 2026Not yet reached.

Upcoming

  1. 2026First APJ IND filing (next)
Primer